<![CDATA[PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data]]>

Data ReadoutpositiveamivantamabPositive

AI Analysis

Summary

PALOMA-2 trial showed improved 3-year survival rates of 70% with amivantamab compared to historical data from the MARIPOSA study. The data suggests a survival benefit for the intravenous formulation in cancer treatment.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

PALOMA-2 demonstrated 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab

Importance:6/10

Sentiment:

0.70

oncologyclinical trial datasurvival benefitcomparative efficacy

Read the original article

Published by Cancer Network on September 16, 2026 7:00 PM

Read Original